4.73
0.03 (0.64%)
| Previous Close | 4.70 |
| Open | 4.74 |
| Volume | 277,953 |
| Avg. Volume (3M) | 472,458 |
| Market Cap | 279,491,456 |
| Price / Earnings (Forward) | 89.29 |
| Price / Sales | 1.29 |
| Price / Book | 0.540 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -21.98% |
| Operating Margin (TTM) | -81.99% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Total Debt/Equity (MRQ) | 2.30% |
| Current Ratio (MRQ) | 3.92 |
| Operating Cash Flow (TTM) | -56.47 M |
| Levered Free Cash Flow (TTM) | -41.71 M |
| Return on Assets (TTM) | -7.05% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vanda Pharmaceuticals Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 0.5 |
| Average | -0.38 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 78.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Krensavage Asset Management, Llc | 30 Jun 2025 | 1,024,883 |
| 52 Weeks Range | ||
| Median | 20.00 (322.83%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Aug 2025 | 20.00 (322.83%) | Buy | 4.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera |
| 28 Aug 2025 | Announcement | Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences |
| 21 Aug 2025 | Announcement | Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz® |
| 18 Aug 2025 | Announcement | In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder |
| 31 Jul 2025 | Announcement | Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results |
| 23 Jul 2025 | Announcement | Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |